Regenicin (Regenicin) Total Stockholders Equity : $-6.21 Mil (As of Mar. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Regenicin Total Stockholders Equity?

Regenicin's Total Stockholders Equity for the quarter that ended in Mar. 2023 was $-6.21 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Regenicin's Book Value per Share for the quarter that ended in Mar. 2023 was $-0.04. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Regenicin's Debt-to-Equity for the quarter that ended in Mar. 2023 was -0.10.

Regenicin Total Stockholders Equity Historical Data

The historical data trend for Regenicin's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Total Stockholders Equity Chart

Regenicin Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Total Stockholders Equity

Get a 7-Day Free Trial

-3.00

-3.73

-4.29

-4.96

-5.60

Regenicin Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Total Stockholders Equity	Get a 7-Day Free Trial															-5.28	-5.44	-5.60	-5.88	-6.21

Regenicin (OTCPK:RGIN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Regenicin's Book Value per Share for the quarter that ended in Mar. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-6.211	-	0.001)	/	153.483
	=	-0.04

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Regenicin's Debt-to-Equity for the quarter that ended in Mar. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.643	+	0)	/	-6.211
	=	-0.10

Regenicin Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Regenicin's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenicin (Regenicin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 High Court, Little Falls, NJ, USA, 07424

Website

https://www.regenicin.com

Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines